知名药企，突然暴涨超115%！

Core Viewpoint - The article highlights the significant surge in the stock price of the biotech company,药捷安康, which increased by nearly 116% in a single day, contributing to a substantial rise in the 18A sector of unprofitable biotech companies in Hong Kong [12][18]. Group 1: Stock Performance - 药捷安康's stock opened and surged to a high of 124.10%, closing at 415.00 HKD per share, marking a 115.58% increase [12][24]. - Over four trading days, 药捷安康's stock price has cumulatively risen by nearly 500% [18]. - The overall 18A sector, which includes unprofitable biotech companies, saw an increase of 15.63%, leading all concept sectors [20]. Group 2: Market Reactions - Following 药捷安康's announcement regarding its clinical trial for its core product, the stock price of several other companies in the 18A sector also rose significantly, with notable increases such as 脑动极光 up 34.93% and MIRXES up 25.91% [23]. - The article mentions that the Hong Kong stock market saw a general uptick, with the Hang Seng Index rising by 0.22% and the Hang Seng Tech Index increasing by 0.91% [2][4]. Group 3: Industry Developments - The article notes that the automotive sector, particularly the new energy vehicle industry, is also experiencing a positive trend, with companies like 宁德时代 and 理想汽车 seeing significant stock price increases [26][32]. - The Chinese government has introduced measures to stabilize the automotive industry, which includes a commitment from 17 major vehicle manufacturers to ensure supplier payment terms do not exceed 60 days [32].